Avi Ashkenazi
Cited by
Cited by
Death receptors: signaling and modulation
A Ashkenazi, VM Dixit
science 281 (5381), 1305-1308, 1998
Safety and antitumor activity of recombinant soluble Apo2 ligand
A Ashkenazi, RC Pai, S Fong, S Leung, DA Lawrence, SA Marsters, ...
The Journal of clinical investigation 104 (2), 155-162, 1999
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
RM Pitti, SA Marsters, S Ruppert, CJ Donahue, A Moore, A Ashkenazi
Journal of Biological Chemistry 271 (22), 12687-12690, 1996
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
JP Sheridan, SA Marsters, RM Pitti, A Gurney, M Skubatch, D Baldwin, ...
Science 277 (5327), 818-821, 1997
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
A Ashkenazi
Nature Reviews Cancer 2 (6), 420-430, 2002
Apoptosis control by death and decoy receptors
A Ashkenazi, VM Dixit
Current opinion in cell biology 11 (2), 255-260, 1999
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
FC Kischkel, DA Lawrence, A Chuntharapai, P Schow, KJ Kim, ...
Immunity 12 (6), 611-620, 2000
Apo2L/TRAIL and its death and decoy receptors
HN LeBlanc, A Ashkenazi
Cell Death & Differentiation 10 (1), 66-75, 2003
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
RM Pitti, SA Marsters, DA Lawrence, M Roy, FC Kischkel, P Dowd, ...
Nature 396 (6712), 699-703, 1998
Distinct primary structures, ligand‐binding properties and tissue‐specific expression of four human muscarinic acetylcholine receptors.
EG Peralta, A Ashkenazi, JW Winslow, DH Smith, J Ramachandran, ...
The EMBO journal 6 (13), 3923-3929, 1987
Assays and methods using biomarkers
A Ashkenazi, K Wagner
US Patent App. 11/542,527, 2007
A novel receptor for Apo2L/TRAIL contains a truncated death domain
SA Marsters, JP Sheridan, RM Pitti, A Huang, M Skubatch, D Baldwin, ...
Current Biology 7 (12), 1003-1006, 1997
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
D Lawrence, Z Shahrokh, S Marsters, K Achilles, D Shih, B Mounho, ...
Nature medicine 7 (4), 383-385, 2001
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
A Ashkenazi, WJ Fairbrother, JD Leverson, AJ Souers
Nature reviews drug discovery 16 (4), 273-284, 2017
Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes
EG Peralta, A Ashkenazi, JW Winslow, J Ramachandran, DJ Capon
Nature 334 (6181), 434-437, 1988
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
A Almasan, A Ashkenazi
Cytokine & growth factor reviews 14 (3-4), 337-348, 2003
Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling
Z Jin, Y Li, R Pitti, D Lawrence, VC Pham, JR Lill, A Ashkenazi
Cell 137 (4), 721-735, 2009
Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8
FC Kischkel, DA Lawrence, A Tinel, H LeBlanc, A Virmani, P Schow, ...
Journal of Biological Chemistry 276 (49), 46639-46646, 2001
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL
KW Wagner, EA Punnoose, T Januario, DA Lawrence, RM Pitti, ...
Nature medicine 13 (9), 1070-1077, 2007
Death receptor signal transducers: nodes of coordination in immune signaling networks
NS Wilson, V Dixit, A Ashkenazi
Nature immunology 10 (4), 348-355, 2009
The system can't perform the operation now. Try again later.
Articles 1–20